Search Results

You are looking at 1 - 10 of 334 items for :

Clear All
Restricted access

Mimi I Hu, Rossella Elisei, Marek Dedecjus, Aron Popovtzer, Maralyn Druce, Ellen Kapiteijn, Furio Pacini, Laura Locati, Jolanta Krajewska, Richard Weiss and Robert F Gagel

several unexplained deaths in the vandetanib treatment group. To address this concern and to help inform decision-making on vandetanib starting doses, this study was designed to identify the objective response rates (ORR) and evaluate the safety and

Free access

Kimberly Kamp, Brenda Gumz, Richard A Feelders, Dik J Kwekkeboom, Gregory Kaltsas, Frederico P Costa and Wouter W de Herder

-differentiated (WHO grades 1 and 2) GEP-NETs with progressive disease (PD), with a well-established safety profile ( Yao et al . 2008 , 2010 , 2011 , Pavel et al . 2011 ). In the randomized phase III RADIANT-3 study, everolimus therapy was associated with a 2

Open access

Marianne Pavel, David J Gross, Marta Benavent, Petros Perros, Raj Srirajaskanthan, Richard R P Warner, Matthew H Kulke, Lowell B Anthony, Pamela L Kunz, Dieter Hörsch, Martin O Weickert, Pablo Lapuerta, Wenjun Jiang, Kenneth Kassler-Taub, Suman Wason, Rosanna Fleming, Douglas Fleming and Rocio Garcia-Carbonero

Pharmaceuticals 2017 , National Comprehensive Cancer Network 2017 ). In this international, multicenter, randomized, double-blind, placebo-controlled phase 3 companion study, TELECAST, the safety and efficacy of telotristat ethyl were assessed in patients with

Open access

Francis Worden, Martin Fassnacht, Yuankai Shi, Tatiana Hadjieva, Françoise Bonichon, Ming Gao, Laura Fugazzola, Yuichi Ando, Yasuhisa Hasegawa, Do Joon Park, Young Kee Shong, Johannes W A Smit, John Chung, Christian Kappeler, Gerold Meinhardt, Martin Schlumberger and Marcia S Brose

demonstrated a consistent safety profile across tumor types. AEs associated with sorafenib are predominantly grade 1/2, non-life threatening, and manageable. The most commonly reported AEs include hand–foot skin reaction (HFSR), rash/desquamation, hypertension

Open access

Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Edda Gomez-Panzani, Philippe Ruszniewski and on behalf of the CLARINET Investigators

 mg) open-label extension (OLE) to the core study. The primary objective of the OLE study was to investigate the long-term safety of lanreotide in patients with pancreatic and intestinal NETs. Safety/tolerability of lanreotide was investigated not only

Free access

Roman Vangoitsenhoven, Chantal Mathieu and Bart Van der Schueren

inducing hypoglycemia. In addition, they have an excellent metabolic safety profile and are weight neutral or induce weight loss. However, as with any new class of drugs, caution is warranted. In particular, because these drugs will be used by patients for

Free access

Matthew H Kulke, Thomas O'Dorisio, Alexandria Phan, Emily Bergsland, Linda Law, Phillip Banks, Joel Freiman, Kenny Frazier, Jessica Jackson, James C Yao, Larry Kvols, Pablo Lapuerta, Brian Zambrowicz, Douglas Fleming and Arthur Sands

excess serotonin production and carcinoid syndrome, we explored the safety and efficacy of telotristat etiprate in patients with carcinoid syndrome and diarrhea inadequately controlled by octreotide in a prospective, randomized study. Patients and methods

Free access

Sara Redaelli, Ivan Plaza-Menacho and Luca Mologni

, ZD6474, Genzyme Corp), an orally available kinase inhibitor active against VEGFR2 and EGFR, was later found to be also a potent RET inhibitor ( Carlomagno et al. 2002 , Wedge et al. 2002 , Vidal et al. 2005 ). The efficacy and safety of

Open access

Sakine Sever, Donna L White and José M Garcia

nonsignificant increase in IGF1 level was also observed with anamorelin vs placebo in the murine lung cancer study ( Northrup et al. 2013 ). General long-term clinical safety and efficacy data for anamorelin have recently become available. Data from ROMANA 3

Free access

David J Gross, Gabriel Munter, Menachem Bitan, Tali Siegal, Alberto Gabizon, Ronny Weitzen, Ofer Merimsky, Aliza Ackerstein, Asher Salmon, Avishai Sella and Shimon Slavin

Group-author : The Israel Glivec in Solid Tumors Study Group

received IM orally 400 mg/day for an exposure period of up to 12 months, providing that the patient was considered to benefit from the treatment and the absence of safety concerns. In the event of lack of response, the dosage could be increased to 600 mg